Clariane launches retention boosting universal employee shareholding plan
France-based health and social care group Clariane (formerly Korian) has this month launched a universal employee shareholding initiative (“Together”) designed to involve each of the Group’s 69,000 European staff in long-term value creation while reinforcing the company’s purpose-driven culture. The free share allocation after three years looks set to encourage loyalty in a talent-scarce care sector. Vesting is conditional on…
Ottobock IPOs with €4.bn Frankfurt Stock Exchange listing
German prosthetics maker Ottobock successfully completed its initial public offering (IPO) on the Frankfurt Stock Exchange on October 9, marking the largest German IPO since March 2024 and achieving a market valuation of €4.2 billion. Shares opened at €72 —9% above the offer price. The Naeder family (owners of Näder Holding, a management and investment company that is the majority…
CFO relocation stateside sparks rumours of transatlantic pivot
British multinational Smith & Nephew’s decision to base Chief Financial Officer John Rogers in the United States marks more than a change of address; it underscores the medical-technology group’s growing American centre of gravity and re-ignites debate over a potential shift of the company’s corporate and listing domicile. Rogers has been employed in the U.S. since September 29, after spending…
Royal London Asset Management launches £1bn private healthcare REIT
Royal London Asset Management Property (RLAMP) has launched the RLAM Healthcare REIT, a private, unlisted real estate investment trust with £1 billion of committed capital dedicated to expanding modern care home infrastructure across the UK. The REIT will target purpose-built care homes in high-demand locations, leveraging RLAMP’s expertise after deploying £350 million into healthcare assets since 2022, and integrating Shoreline Partners (a UK-based real estate asset management company…
Post-closing implications as EssilorLuxottica closes Optegra acquisition
EssilorLuxottica has closed the purchase of Optegra, a 70-clinic ophthalmology network spanning the UK, Czech Republic, Poland, Slovakia and the Netherlands. The transaction vaults the group from a dominant eyewear manufacturer-retailer into a vertically integrated eye-health services platform capable of owning the entire patient journey—from screening and diagnosis to surgery, prescription, and connected eyewear. How will this reshape the global…
Novo Nordisk trims 11% of workforce to refocus on diabetes and obesity core
Danish multinational pharmaceutical company Novo Nordisk’s September restructuring marks its largest organisational reset in decades. The Denmark-based group is in the process of eliminating around 9,000 of 78,400 positions (c. 5,000 in Denmark) as it seeks to simplify decision-making, free up capital and defend leadership in the increasingly crowded GLP-1 diabetes-and-obesity arena. With headcount having risen 73 % since 2020, new…
Novo Nordisk appoints new president and CEO as it focuses on U.S. weight-loss drug market
Novo Nordisk appointed Maziar Mike Doustdar as its new CEO and president on August 7, 2025, signalling a strategic shift to address challenges in the U.S. weight-loss drug market and competition from Eli Lilly. Doustdar, the first non-Danish leader in the company’s history, emphasised refocusing on the firm’s core strengths in obesity and diabetes while trimming its pipeline to prioritize speed and execution. His…
AstraZeneca announces $50bn pharma and R&D investment in US by 2030
Global biopharmaceutical company AstraZeneca has announced a $50 billion investment in the United States by 2030 to expand its pharmaceutical manufacturing and R&D footprint. The initiative, unveiled on July 22, 2025, includes a proposed multi-billion-dollar manufacturing facility in Virginia focused on chronic disease treatments such as oral GLP-1s, baxdrostat for hypertension, and PCSK9 inhibitors, which will be the company’s largest single-site investment globally. This expansion…